The Company’s inventory as of February 29, 2020 and May 31, 2019 was $15,895,589 and $0, respectively. Inventory as of February 29, 2020 consisted solely of specialized raw material purchased for use in the commercial manufacturing of pre-launch inventories of Vyrologix to support the Company’s expected approval of the product as a combination therapy for HIV patients in the United States. https://www.sec.gov/Archives/edgar/data/1175680/000119312520102675/d859184d10q.htm